Cyclic RGD Peptide in the Treatment of DMGS

环状RGD肽治疗DMGS

基本信息

项目摘要

DESCRIPTION (provided by candidate) The hallmark pathologic feature of diabetic glomerulosclerosis is mesangial expansion. In diabetic nephropathy (DN), mesangial expansion is the critical lesion that leads to the known clinical features. Increased levels of glucose, insulin, and angiotensin II (ANG ll) both cooperatively and independently stimulate the production of transforming growth factor-beta 1, which then promotes extracellular matrix (ECM) protein expansion, particularly fibronectin, laminin and collagen, by upregulating their synthesis and down-regulating their degradation. Interaction between MCs and ECM proteins occur via integrin receptors (with alpha and beta sub-units), which can be blocked by synthetic Arg-Gly-Asp (RGD) peptides and integrin antibodies. Unlike antiserum, which may cause severe side effects, cyclic RGD peptides are currently available as an effective anti-thrombotic and anti-cancer agent in humans as well as in treating ischemia-induced acute renal failure in rats. However, no-one has looked at the potential benefit of RGD peptides in treating DN. Integrin signaling is important in cellular physiology and pathophysiology. RGD peptides have also been used to define the mechanisms of integrin-mediated signaling in other cell types, but not in MC. The hypothesis of this application is that integrin-mediated attachment induces positive feedback of integrin and ECM gene expression in DN. Our preliminary studies show that RGD peptides significantly inhibited MC adhesion to fibronectin, laminin and collagen and significantly increased alpha 1, alpha 5, and beta 1 integrin sub-units in glomeruli of streptozotocin (STZ)-induced diabetic rats. Also, ANG II and insulin increased integrin expression and the IC50 of RGD peptide to inhibit MC fibronectin adhesion. The Specific Aims are 1) to quantitate the effects of cyclic RGD peptides on the progression of DMGS in STZ-induced diabetic rats; 2) to determine whether FAK, the MAPK and Pl3 kinase signaling pathways are activated by integrin-mediated MC-ECM adhesion, using RGD peptides. The successful completion of this study can provide a novel and feasible target for treatment in DN.
描述(由候选人提供) 糖尿病肾小球硬化的标志性病理特征是系膜 扩张.在糖尿病肾病(DN)中,系膜扩张是关键的, 导致已知临床特征的病变。葡萄糖水平升高, 胰岛素和血管紧张素II(ANG II)协同或独立 刺激转化生长因子β 1的产生, 促进细胞外基质(ECM)蛋白扩增,特别是 纤连蛋白、层粘连蛋白和胶原蛋白,通过上调它们的合成, 下调它们的降解。MCs和ECM蛋白之间的相互作用 通过整合素受体(具有α和β亚单位)发生, 被合成的Arg-Gly-Asp(RGD)肽和整联蛋白抗体阻断。不像 抗血清,这可能会导致严重的副作用,环RGD肽是 目前可作为有效的抗血栓形成和抗癌剂, 人以及治疗大鼠中缺血诱导的急性肾衰竭。 然而,没有人研究过RGD肽在治疗糖尿病中的潜在益处。 DN.整合素信号传导在细胞生理学和病理生理学中是重要的。 RGD肽也已被用于定义整合素介导的细胞凋亡的机制。 在其他细胞类型中,但不在MC中。这个假设 应用是整合素介导的附着诱导正反馈 DN中整合素和ECM基因表达。我们的初步研究表明, 肽显著抑制MC与纤连蛋白、层粘连蛋白和 胶原蛋白和显著增加的α 1,α 5和β 1整合素 链脲佐菌素(STZ)诱导的糖尿病大鼠肾小球中的亚单位。此外,ANG II和胰岛素增加整合素表达和RGD肽的IC 50, 抑制MC纤连蛋白粘附。具体目标是:1)定量 环RGD肽对STZ诱导的DMGS进展的影响 糖尿病大鼠; 2)检测FAK、MAPK和P13激酶信号转导通路是否与糖尿病大鼠的糖尿病模型相一致。 整合素介导的MC-ECM粘附激活通路,使用RGD 缩氨酸这项研究的成功完成可以提供一个新的和 DN治疗的可行靶点。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susanne B Nicholas其他文献

Susanne B Nicholas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susanne B Nicholas', 18)}}的其他基金

Development Core
开发核心
  • 批准号:
    10285907
  • 财政年份:
    2021
  • 资助金额:
    $ 12.18万
  • 项目类别:
Development Core
开发核心
  • 批准号:
    10657819
  • 财政年份:
    2021
  • 资助金额:
    $ 12.18万
  • 项目类别:
Cyclic RGD Peptide in the Treatment of DMGS
环状RGD肽治疗DMGS
  • 批准号:
    6749567
  • 财政年份:
    2002
  • 资助金额:
    $ 12.18万
  • 项目类别:
Cyclic RGD Peptide in the Treatment of DMGS
环状RGD肽治疗DMGS
  • 批准号:
    6623935
  • 财政年份:
    2002
  • 资助金额:
    $ 12.18万
  • 项目类别:
Cyclic RGD Peptide in the Treatment of DMGS
环状RGD肽治疗DMGS
  • 批准号:
    6471156
  • 财政年份:
    2002
  • 资助金额:
    $ 12.18万
  • 项目类别:
Genetics of Diabetic Nephropathy in Mexican-Americans a*
墨西哥裔美国人糖尿病肾病的遗传学a*
  • 批准号:
    7126543
  • 财政年份:
    1999
  • 资助金额:
    $ 12.18万
  • 项目类别:
GENETICS OF DIABETIC NEPHROPATHY IN HISPANICS
西班牙裔糖尿病肾病的遗传学
  • 批准号:
    6660718
  • 财政年份:
    1999
  • 资助金额:
    $ 12.18万
  • 项目类别:
Genetics /Diabetic Nephropathy /Mexican-Americans /Afric
遗传学/糖尿病肾病/墨西哥裔美国人/非洲
  • 批准号:
    7036303
  • 财政年份:
    1999
  • 资助金额:
    $ 12.18万
  • 项目类别:

相似海外基金

A novel mechanism of cell growth regulation by the intrinsically disordered protein, NPM1
内在无序蛋白 NPM1 调节细胞生长的新机制
  • 批准号:
    26440021
  • 财政年份:
    2014
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on the mechanism of cell growth regulation by ST2 and its possible anti-cancerous effect.
ST2调节细胞生长的机制及其可能的抗癌作用研究。
  • 批准号:
    25460393
  • 财政年份:
    2013
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular Mechanisms for cell growth regulation by Mnk-mediated translational control
Mnk 介导的翻译控制调节细胞生长的分子机制
  • 批准号:
    24590105
  • 财政年份:
    2012
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Phosphatidylcholine Metabolism with Cell Growth Regulation
将磷脂酰胆碱代谢与细胞生长调节相结合
  • 批准号:
    221878
  • 财政年份:
    2010
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Operating Grants
UNDERSTANDING THE ROLES OF SMALL GTPASES IN CELL GROWTH REGULATION
了解小 GTP 酶在细胞生长调节中的作用
  • 批准号:
    7955176
  • 财政年份:
    2009
  • 资助金额:
    $ 12.18万
  • 项目类别:
Roles of the Golgi apparatus in cell growth regulation
高尔基体在细胞生长调节中的作用
  • 批准号:
    18570173
  • 财政年份:
    2006
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanism of cell growth regulation by small G proteins
小G蛋白调节细胞生长的机制
  • 批准号:
    17014061
  • 财政年份:
    2005
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research on Priority Areas
The role of Kaiso in cell growth regulation
Kaiso 在细胞生长调节中的作用
  • 批准号:
    302718-2004
  • 财政年份:
    2004
  • 资助金额:
    $ 12.18万
  • 项目类别:
    Postgraduate Scholarships - Master's
Bone Cell Growth Regulation by Runx2/Cbfa1
Runx2/Cbfa1 调节骨细胞生长
  • 批准号:
    6619987
  • 财政年份:
    2003
  • 资助金额:
    $ 12.18万
  • 项目类别:
Bone Cell Growth Regulation by Runx2/Cbfa1
Runx2/Cbfa1 调节骨细胞生长
  • 批准号:
    6898940
  • 财政年份:
    2003
  • 资助金额:
    $ 12.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了